FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia By Ogkologos - December 3, 2024 900 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Patients with Advanced RCC Following Progression to PD1 or PD-L1 Inhibitors Combining 177Lu-PSMA-617 with ADT Plus ARPI Prolongs rPFS in Patients with PSMA-positive Metastatic Androgen Pathway Modulator-Naive/Sensitive Prostate Cancer EMA Recommends Extension of Therapeutic Indications for Cetuximab MOST POPULAR Copanlisib Shows Promising Clinical Activity in Select Tumours with PIK3CA Mutation... February 14, 2022 Loving Yourself April 7, 2021 Enzalutamide Gets Added Approval for Prostate Cancer That Hasn’t Spread January 5, 2024 Study Examines Whether Blood Test Can Identify Early Cancers June 2, 2020 Load more HOT NEWS Early Signs of Efficacy of New Targeted Agents and Immunotherapies Reported... EMA Recommends Granting a Marketing Authorisation for the Medicinal Product Nyvepria The digital shift: How are remote GP appointments affecting cancer patients? Liquid Biopsy Detects Brain Cancer and Early-Stage Kidney Cancer
